FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
investigational tumor-infiltrating lymphocyte (TIL) therapy, LN-145, in certain non-small cell lung cancer (NSCLC) patients. This clinical hold was placed by the FDA last year in December following a grade 5 (fatal) adverse effect, potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen observed in the study. The FDA removed the clinical hold after reviewing Iovance's proposal for additional safety measures and monitoring. To develop these measures, management worked closely with the agency officials and an independent data monitoring committee. Owing to the clinical hold, IOVA had paused enrollment of new patients in the IOV-LUN-202 study. Following the removal of the hold, management restarted enrolling patients in the study and intends to enroll a total of around 120 patients by the next year. The IOV-LUN-202 study is evaluating LN-145 for treating patients who have progressed on or after chemotherapy and anti-PD-1 therapy for advanced (unresec
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024GlobeNewswire
- Iovance Biotherapeutics to Present at Upcoming Conferences [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics to Present at Upcoming ConferencesGlobeNewswire
- With 63% ownership of the shares, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is heavily dominated by institutional owners [Yahoo! Finance]Yahoo! Finance
- Where Will Iovance Biotherapeutics Stock Be in 5 Years? [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 2/28/24 - Miss
IOVA
Sec Filings
- 5/1/24 - Form ARS
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- IOVA's page on the SEC website